Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of Bi-monthly Intermittent Preventive Treatment With Mefloquine-Artesunate or Sulfadoxine-Pyrimethamine Plus Amodiaquine for Prevention of Malaria and Related Complications in Patients With Sickle Cell Anaemia.

NCT01319448 is registered in ClinicalTrials.gov with London School of Hygiene and Tropical Medicine as lead sponsor.

NCT NCT01319448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01319448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of Bi-monthly Intermittent Preventive Treatment With Mefloquine-Artesunate or Sulfadoxine-Pyrimethamine Plus Amodiaquine for Prevention of Malaria and Related Complications in Patients With Sickle Cell Anaemia.
Lead sponsor
London School of Hygiene and Tropical Medicine
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2011
Completion date
April 30, 2013
Enrollment
270 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, sickle cell crisis